Semaglutide improves fatty liver disease and inflammation in people with HIV
Women with HIV need tailored advice on statins and heart disease risk
Progress in reducing new HIV diagnoses much slower for Black men in the US
The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance become a problem?
Ultra-long-acting cabotegravir could be taken three times a year for HIV PrEP and treatment
HIV medication dolutegravir not linked with increased blood pressure during pregnancy
Switch to an integrase inhibitor leads to greater weight during and after the menopause
Huge increase in PrEP uptake when services offer choice, flexibility and injectable PrEP, African study shows
Far fewer HIV infections in Australian PrEP users – consistent use is key
